What is the recommended iron supplementation regimen for an adult with iron‑deficiency anemia secondary to lower gastrointestinal bleeding who is hemodynamically stable and can tolerate oral medication?

Oral Iron Supplementation for Iron-Deficiency Anemia Secondary to Lower Gastrointestinal Bleeding

First-Line Recommendation

Start ferrous sulfate 200 mg (65 mg elemental iron) once daily in the morning on an empty stomach, together with 250–500 mg vitamin C, and continue for 3 months after hemoglobin normalizes (total duration approximately 6–7 months). 1

---

Optimal Oral Iron Regimen

Formulation and Dosing

• Ferrous sulfate remains the gold standard because it is the most cost-effective formulation (approximately £1.00 vs £47.60 for alternatives per 28-day supply), and no other oral iron preparation has demonstrated superior efficacy or tolerability. 1
• Administer 50–100 mg elemental iron once daily (one ferrous sulfate 200 mg tablet provides ~65 mg elemental iron). 1
• Once-daily dosing is superior to multiple daily doses because elemental iron ≥60 mg triggers a hepcidin surge lasting 24–48 hours, which reduces absorption of subsequent doses by 35–45% and increases gastrointestinal side effects without improving hemoglobin response. 1

Timing and Co-Administration

• Take iron on an empty stomach (1–2 hours before or after meals) to maximize absorption by up to 50%. 1
• Co-administer 250–500 mg vitamin C with each iron dose to form a soluble chelate and enhance absorption, especially when transferrin saturation is low. 1
• Avoid tea, coffee, or calcium-containing foods within 1–2 hours of the iron dose, as these markedly reduce absorption. 1
• If gastrointestinal intolerance occurs, taking iron with a small amount of food is acceptable, though absorption will be lower. 1

Alternative Oral Formulations (if ferrous sulfate not tolerated)

• Ferrous fumarate (69–106 mg elemental iron per tablet) or ferrous gluconate (35–38 mg elemental iron per tablet) provide equivalent efficacy when ferrous sulfate is not tolerated, though they are generally more expensive. 1
• Alternate-day dosing (100–200 mg elemental iron every other day) markedly increases fractional iron absorption, reduces gastrointestinal side effects, and maintains overall efficacy, though the early rate of hemoglobin rise may be slower. 1
• Do not use modified-release preparations, as they release iron beyond the duodenum (the primary absorption site) and are classified as "less suitable for prescribing" by the British National Formulary. 1

---

Monitoring Protocol

Week 2 Assessment

• Check hemoglobin at 2 weeks; an increase of ≥10 g/L (≈1 g/dL) predicts treatment success with 90% sensitivity and 79% specificity. 1, 2
• Failure to achieve a ≥10 g/L rise strongly predicts overall treatment failure and should prompt evaluation for non-adherence, ongoing blood loss, malabsorption, or concurrent vitamin B12/folate deficiency. 1, 2

Week 4 and Beyond

• Re-measure hemoglobin at 4 weeks and continue monitoring every 4 weeks until hemoglobin normalizes. 1, 2
• After hemoglobin normalization, continue oral iron for an additional 3 months to fully replenish iron stores, resulting in a total treatment duration of approximately 6–7 months. 1, 2

Post-Treatment Surveillance

• After successful treatment, monitor blood counts every 3 months for the first year, then again after the second year to detect recurrent iron deficiency. 2
• Re-initiate therapy if hemoglobin or MCV falls below normal. 2

---

Indications for Switching to Intravenous Iron

Consider intravenous iron when oral therapy fails or is inappropriate:

• Intolerance to ≥2 different oral iron preparations (e.g., ferrous sulfate and ferrous fumarate or gluconate). 1
• Ferritin fails to improve after 4 weeks of compliant oral therapy despite adequate dosing and vitamin C supplementation. 1
• Active inflammatory bowel disease with hemoglobin <10 g/dL, where inflammation-induced hepcidin elevation impairs oral iron absorption and oral iron may exacerbate intestinal inflammation. 1, 3
• Post-bariatric surgery patients, in whom duodenal iron absorption is anatomically disrupted. 1, 4
• Celiac disease with inadequate response to oral iron despite strict adherence to a gluten-free diet. 1, 4
• Ongoing significant lower GI bleeding that exceeds the capacity of oral iron to replenish losses. 5

Preferred Intravenous Formulations

• Ferric carboxymaltose (750–1000 mg per 15-minute infusion) or ferric derisomaltose (1000 mg single infusion) can replenish iron deficits in 1–2 sessions. 1, 6
• Intravenous iron produces a clinically meaningful hemoglobin rise within 7 days and should be considered an alternative to blood transfusion in most cases. 1
• All approved intravenous iron products have comparable safety; true anaphylaxis is exceedingly rare (<1%), and most adverse reactions are complement-activation-related pseudo-allergic infusion reactions that respond to antihistamines and corticosteroids. 1, 6

---

Common Pitfalls to Avoid

• Do not prescribe multiple daily doses of iron; hepcidin-mediated blockade prevents absorption of second and third doses and increases gastrointestinal adverse effects without improving efficacy. 1
• Do not discontinue iron when hemoglobin normalizes; continue therapy for an additional 3 months to restore iron stores. 1, 2
• Do not persist with oral iron beyond 4 weeks without a hemoglobin rise; reassess adherence, malabsorption, ongoing blood loss, or need for intravenous iron. 1, 2
• Do not omit vitamin C supplementation when the oral response is suboptimal, as it significantly enhances absorption. 1
• Do not switch between different ferrous salts (ferrous sulfate, ferrous fumarate, ferrous gluconate) expecting better tolerability, as evidence does not support this practice. 1
• Do not use multivitamin preparations as the sole iron source, as they typically contain insufficient elemental iron (≤14 mg) for treating iron deficiency anemia. 1

---

Special Considerations for Lower GI Bleeding

• Address the underlying cause of bleeding while simultaneously replenishing iron stores; iron supplementation alone is insufficient if active bleeding continues. 4, 3
• Red cell transfusion should be reserved only for severe symptomatic anemia or circulatory compromise, not for chronic stable anemia that can be managed with iron replacement. 2, 5
• In patients with ongoing chronic blood loss that exceeds oral iron replacement capacity, intravenous iron is preferred over repeated transfusions. 5, 3